Why the study?
Can erlotinib treatment cause acute myocardial infarction in patients with NSCLC?
Can erlotinib treatment cause acute myocardial infarction in patients with NSCLC?
Erlotinib treatment in NSCLC patients may be associated with acute myocardial infarction, highlighting the need for careful cardiac monitoring in susceptible individuals.
May warrant cardiac monitoring with erlotinib; this first case leaves open causality and need for confirmation.
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: